- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
Please click here To request a Patient Resource Kit for VELCADE® (bortezomib). This complimentary kit includes information about VELCADE for multiple myeloma or relapsed MCL along with tools to help you manage your disease.
VELCADE may be able to help treat your multiple myeloma or relapsed mantle cell lymphoma.
VELCADE is the first treatment approved by the FDA from a class of medicines called proteasome inhibitors. VELCADE is an effective treatment for patients with multiple myeloma and relapsed mantle cell lymphoma and is given intravenously as a 3- to 5-second injection. To date, more than 160,000 patients have been treated with VELCADE.* Learn how proteasome inhibitors work.
VELCADE can be used to treat many patients, including the elderly and those with kidney disease.
VELCADE should not be used in patients who are pregnant, planning to become pregnant or breastfeeding, as well as those who are allergic or hyper-sensitive to bortezomib, boron or mannitol, the ingredients VELCADE is made of.
You and your doctor will discuss your treatment options to decide if VELCADE is an option for you. Learn more about considering VELCADE.